MarketCap
DBV Technologies S.A. DBVT
$ 11.85
2.6%
Facebook
X
Telegram
DBV Technologies S.A. Total Liabilities | DBVT
Annual Total Liabilities DBV Technologies S.A.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64.9 M | 38.3 M | 42.8 M | 52.1 M | 47.4 M | 66.8 M | 78.5 M | 50.5 M | 47.9 M | 44.7 M | 21.2 M | 9.97 M | 5.84 M | 3.8 M | 4.01 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 78.5 M | 3.8 M | 38.6 M |
Quarterly Total Liabilities DBV Technologies S.A.
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.7 M | 62.8 M | 58.4 M | 64.9 M | 57.6 M | 57.2 M | 47.7 M | 38.3 M | 39 M | 35.1 M | 34.2 M | 42.8 M | 45.8 M | 53.3 M | 53.8 M | 52.1 M | 36.1 M | - | 35.5 M | 47.4 M | 54 M | 57.6 M | 52.2 M | 66.8 M | 66.8 M | 66.8 M | 66.8 M | 78.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 78.5 M | 34.2 M | 53.3 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLineRx Ltd.
BLRX
|
17.6 M | $ 1.49 | -1.97 % | $ 3.67 B |  Israel |
 |
Sage Therapeutics
SAGE
|
82.1 M | - | - | $ 527 M |  USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
69.2 M | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
344 M | - | - | $ 121 M | USA |
 |
TCR2 Therapeutics
TCRR
|
67.4 M | - | - | $ 58.1 M | USA |
 |
C4 Therapeutics
CCCC
|
102 M | $ 2.9 | -3.5 % | $ 240 M | USA |
 |
Eli Lilly and Company
LLY
|
36.6 B | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
37.9 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Compugen Ltd.
CGEN
|
18.5 M | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
134 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
GeoVax Labs
GOVX
|
2.52 M | $ 2.13 | -20.4 % | $ 2.04 M | USA |
 |
Unity Biotechnology
UBX
|
31.2 M | - | -33.41 % | $ 3.37 M | USA |
 |
MediciNova
MNOV
|
4.02 M | $ 1.41 | 0.36 % | $ 69.2 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
59.5 M | - | - | $ 521 M | USA |
 |
Seelos Therapeutics
SEEL
|
38.9 M | - | -47.76 % | $ 6.27 M | USA |
 |
Celldex Therapeutics
CLDX
|
55.8 M | $ 30.18 | -1.53 % | $ 2 B | USA |
 |
Moderna
MRNA
|
3.69 B | $ 248.62 | -0.88 % | $ 96.7 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
4.7 M | $ 3.96 | 1.41 % | $ 48.3 M | Israel |
 |
Kiromic BioPharma
KRBP
|
21.1 M | - | 6.61 % | $ 3.08 M | USA |
 |
Nektar Therapeutics
NKTR
|
191 M | $ 38.41 | 1.67 % | $ 648 M | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
CorMedix
CRMD
|
421 M | $ 5.31 | -2.23 % | $ 383 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
343 M | $ 45.39 | 0.53 % | $ 4.08 B |  Schweiz |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
5.84 M | $ 1.66 | -2.64 % | $ 1.12 B | Israel |
 |
Deciphera Pharmaceuticals
DCPH
|
123 M | - | - | $ 2.18 B | USA |
 |
Idera Pharmaceuticals
IDRA
|
62.2 M | - | -23.04 % | $ 26.6 M | USA |
 |
Tyme Technologies
TYME
|
7.93 M | - | 8.07 % | $ 54 M | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Verona Pharma plc
VRNA
|
270 M | - | - | $ 69.7 B |  Britain |
 |
Oramed Pharmaceuticals
ORMP
|
11.8 M | $ 4.1 | 3.27 % | $ 170 M | Israel |
 |
Corner Growth Acquisition Corp.
COOL
|
297 K | - | -0.89 % | $ 114 M | USA |
 |
Karuna Therapeutics
KRTX
|
82 M | - | - | $ 12.2 B | USA |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Curis
CRIS
|
14.5 M | $ 0.59 | -9.62 % | $ 7.77 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
55.9 M | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Fusion Pharmaceuticals
FUSN
|
63.4 M | - | - | $ 1.41 B |  Canada |
 |
Завод ДИОД
DIOD
|
195 M | - | - | - |  Russia |
 |
Gritstone Oncology
GRTS
|
126 M | - | 0.42 % | $ 213 M | USA |
 |
Pfizer
PFE
|
121 B | $ 29.42 | 0.19 % | $ 167 B | USA |
 |
HOOKIPA Pharma
HOOK
|
31.3 M | - | -6.92 % | $ 79.4 M | USA |
 |
Guardion Health Sciences
GHSI
|
3.77 M | - | -0.31 % | $ 3.64 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
23.6 M | - | - | $ 109 M | USA |
|
Monopar Therapeutics
MNPR
|
2.89 M | $ 71.83 | 0.07 % | $ 532 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Otonomy
OTIC
|
40.7 M | - | -1.96 % | $ 4.68 M | USA |
 |
Prothena Corporation plc
PRTA
|
46.3 M | $ 8.74 | 2.1 % | $ 470 M | USA |
 |
Exelixis
EXEL
|
683 M | $ 70.73 | 0.21 % | $ 19.2 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
38.9 M | - | 17.91 % | $ 11.1 M | USA |